Neurocrine Biosciences, Inc.
NBIX
Hisse Senetlerindeki Sıralama
#1576
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Hisse Fiyatı
$135.96
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$13.82B
Değişim (1 gün)
-0.72%
Değişim (1 yıl)
-2.95%
Ülke
US
Ticaret Neurocrine Biosciences, Inc. (NBIX)
Kategori
Healthcare
Neurocrine Biosciences, Inc. (NBIX) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: 23.38%
Neurocrine Biosciences, Inc. şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 23.38%'dir. 2023 yılı sonunda şirketin faaliyet marjı 13.30% idi.
Neurocrine Biosciences, Inc. için 2000 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | 23.38% | -3.47% |
| 2024 | 24.22% | 82.11% |
| 2023 | 13.30% | -20.50% |
| 2022 | 16.73% | 85.07% |
| 2021 | 9.04% | -41.98% |
| 2020 | 15.58% | 69.90% |
| 2019 | 9.17% | 12.38% |
| 2018 | 8.16% | -110.04% |
| 2017 | -81.27% | -91.73% |
| 2016 | -982.48% | 106.18% |
| 2015 | -476.51% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -1,701.88% | -62,669.12% |
| 2012 | 2.72% | -93.79% |
| 2011 | 43.82% | -206.98% |
| 2010 | -40.96% | -97.75% |
| 2009 | -1,817.47% | -17.24% |
| 2008 | -2,196.18% | -87.33% |
| 2007 | -17,340.03% | 5,903.75% |
| 2006 | -288.82% | 1,326.98% |
| 2005 | -20.24% | -67.06% |
| 2004 | -61.44% | 45.35% |
| 2003 | -42.27% | -92.64% |
| 2002 | -574.20% | 439.66% |
| 2001 | -106.40% | -56.40% |
| 2000 | -244.04% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 38.59% | -98.35% |
US
|
|
| -149.01% | -106.37% |
US
|
|
| 25.57% | -98.91% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.77% |
NL
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.